share_log

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A：超過5%持股股東披露文件(修正)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)
美股SEC公告 ·  08/05 18:27
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
生物技術公司exicure參股納斯達克（NASDAQ）交易所股票代碼爲XCUR。該公司成爲了2024年7月31日提交給美國證券交易委員會（SEC）的13D/A表格文件的主題。提交的文件顯示CBI USA Inc和DGP Co Ltd的參股金融活動。CBI USA公司是位於特拉華州的企業，報告擁有818,299股普通股，佔exicure普通股的9.5%。總部位於韓國的DGP Co Ltd報告對該公司的3,060,000股普通股享有實際所有權，佔該類股的35.4%。該文件包括修改DGP與Overdigmk之間的股票購買協議的補充聲明，將DGP Sale合同的餘額截止日期延長至2024年9月30日。此外，還簽訂了一份轉讓和放棄協議，允許終止或將DGP Sale Agreement轉讓給DGP要求的第三方。這些文件作爲第13份修正案提交給13D日程表，該13D日程表修改和補充了最初的提交和隨後從2022年6月1日開始的修改。
生物技術公司exicure參股納斯達克（NASDAQ）交易所股票代碼爲XCUR。該公司成爲了2024年7月31日提交給美國證券交易委員會（SEC）的13D/A表格文件的主題。提交的文件顯示CBI USA Inc和DGP Co Ltd的參股金融活動。CBI USA公司是位於特拉華州的企業，報告擁有818,299股普通股，佔exicure普通股的9.5%。總部位於韓國的DGP Co Ltd報告對該公司的3,060,000股普通股享有實際所有權，佔該類股的35.4%。該文件包括修改DGP與Overdigmk之間的股票購買協議的補充聲明，將DGP Sale合同的餘額截止日期延長至2024年9月30日。此外，還簽訂了一份轉讓和放棄協議，允許終止或將DGP Sale Agreement轉讓給DGP要求的第三方。這些文件作爲第13份修正案提交給13D日程表，該13D日程表修改和補充了最初的提交和隨後從2022年6月1日開始的修改。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息